Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Titan Pharma (TTNP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Titan Pharma 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 USA

P: 650-244-4990 F: 650-244-4956

Description:

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

Key Statistics

Overview:

Market Capitalization, $K 4,664
Shares Outstanding, K 21,200
Annual Sales, $ 220 K
Annual Net Income, $ -14,310 K
Last Quarter Sales, $ 2,670 K
Last Quarter Net Income, $ -870 K
36-Month Beta 1.15
% of Insider Shareholders 19.50%
% of Institutional Shareholders 6.50%

Growth:

1-Year Total Return -86.25%
3-Year Total Return -93.80%
5-Year Total Return -94.29%
5-Year Revenue Growth -96.91%
5-Year Earnings Growth 44.88%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 11/08/18
Earnings Per Share ttm -0.53
EPS Growth vs. Prev Qtr 66.67%
EPS Growth vs. Prev Year 76.47%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 2-11 on 09/29/15

TTNP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -0.54
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -1,659.34
Return-on-Assets (Before Tax) -143.63
Net Margin % -203.09
Debt/Equity -4.06
Price/Sales 49.31
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.06
Interest Coverage -37.68
Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar